Endothelial cell dysfunction (ECD) is the harbinger of majority of cardiovascular disease and is especially prevalent in patients with chronic kidney disease (CKD). During the past 2 cycles of this study we obtained and verified genetic and proteomic signatures of ECD. In the process we established a model of pre-clinical """"""""early"""""""" ECD using chronically non-pressor doses of L-NMMA. Renal microvasculature of these mice revealed depletion of 2 key mitochondrial enzymes - enoyl- CoA-hydratase-1 (ECHS-1) and aconitase-2 (Aco-2). Consequently, TCA cycle was inhibited, mitochondrial biogenesis suppressed, and normoxic glycolysis prevailed resulting in the increase of lactate production - a metabolic profile which is a hallmark of Warburg effect. Present application is based on a hypothesis that this metabolic profile of ECD may explain some abnormalities in the pathways of mitochondrial and cytosolic glucose-lipid metabolism. A therapeutic corollary of these findings predicts the possibility of correcting """"""""truncated"""""""" TCA cycle by introducing an intermediate bypassing the enzymatic block potentially resulting in alleviation of ECD. Another major goal consists in obtaining the metabolic signatures of advanced ECD accompanied by hypoxic glycolysis (Pasteur effect). We hypothesize that it is responsible for the induction of HIFs, VEGF, and an increase in vascular permeability.
Four Specific Aims are proposed: 1) profiling glucose metabolism of dysfunctional endothelium: links to redox, lipid metabolism, and glyceroneogenesis;2) metabolic consequences of Pasteur effect (hypoxic glycolysis) in advanced ECD: induction of HIFs, VEGF and increased vascular permeability;3) glutamine bypasses mitochondrial enzymatic blockade in endothelial dysfunction: metabolic and functional consequences;culminating in 4) a proof of principal clinical trial of glutamine supplementation in patients with CKD 3-4. Results of these investigations should offer a detailed picture of metabolic disturbances associated with ECD in vitro and in vivo, have a potential to disclose a mechanistically rational therapeutic intervention to restore metabolism and alleviate manifestations of ECD, and finally test these findings on glutamine supplementation and vascular functions in a pilot clinical trial of a select patient population with CKD 3-4.

Public Health Relevance

Studies proposed in this grant application should shed light on two concepts: 1) incompetence of stem/progenitor cells in Chronic Kidney Disease (CKD) contributes to the insufficient regenerative processes thus accounting in part for progression of disease and 2) stem cell incompetence is reversible and can be pharmacologically corrected thus resulting in reduction of the rate of progression or even regression of disease. Among the potential causes of stem cell incompetence in CKD we shall focus on a) stem cell-related factors and b) stem cell niche-related factors, as well as attempt pharmacologic correction of stem cell incompetence. These studies should supplement the search for mechanisms of progression of CKD by exploring the regenerative potential and its failure in these morbid states and offering alternative therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK045462-14A1
Application #
8103568
Study Section
Pathobiology of Kidney Disease Study Section (PBKD)
Program Officer
Rys-Sikora, Krystyna E
Project Start
1995-09-01
Project End
2015-04-30
Budget Start
2011-09-01
Budget End
2012-04-30
Support Year
14
Fiscal Year
2011
Total Cost
$428,587
Indirect Cost
Name
New York Medical College
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041907486
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Matsumoto, Kei; Xavier, Sandhya; Chen, Jun et al. (2017) Instructive Role of the Microenvironment in Preventing Renal Fibrosis. Stem Cells Transl Med 6:992-1005
Song, J W; Zullo, J A; Liveris, D et al. (2017) Therapeutic Restoration of Endothelial Glycocalyx in Sepsis. J Pharmacol Exp Ther 361:115-121
Lipphardt, Mark; Song, Jong W; Matsumoto, Kei et al. (2017) The third path of tubulointerstitial fibrosis: aberrant endothelial secretome. Kidney Int 92:558-568
Kida, Yujiro; Zullo, Joseph A; Goligorsky, Michael S (2016) Endothelial sirtuin 1 inactivation enhances capillary rarefaction and fibrosis following kidney injury through Notch activation. Biochem Biophys Res Commun 478:1074-9
Zullo, Joseph A; Fan, Jie; Azar, Tala T et al. (2016) Exocytosis of Endothelial Lysosome-Related Organelles Hair-Triggers a Patchy Loss of Glycocalyx at the Onset of Sepsis. Am J Pathol 186:248-58
Lin, Chi Hua Sarah; Chen, Jun; Zhang, Zhongtao et al. (2016) Endostatin and transglutaminase 2 are involved inĀ fibrosis of the aging kidney. Kidney Int 89:1281-92
Kida, Yujiro; Goligorsky, Michael S (2016) Sirtuins, Cell Senescence, and Vascular Aging. Can J Cardiol 32:634-41
Goligorsky, M S; Hirschi, K (2016) Stress-Induced Premature Senescence of Endothelial and Endothelial Progenitor Cells. Adv Pharmacol 77:281-306
Schwarzenberger, Claudia; Sradnick, Jan; Lerea, Kenneth M et al. (2015) Platelets are relevant mediators of renal injury induced by primary endothelial lesions. Am J Physiol Renal Physiol 308:F1238-46
Rabadi, May M; Xavier, Sandhya; Vasko, Radovan et al. (2015) High-mobility group box 1 is a novel deacetylation target of Sirtuin1. Kidney Int 87:95-108

Showing the most recent 10 out of 109 publications